{"id":81899,"date":"2019-04-09T00:00:50","date_gmt":"2019-04-11T06:54:38","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/81899\/"},"modified":"2019-04-11T14:54:40","modified_gmt":"2019-04-11T06:54:40","slug":"87e2d667a2","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/81899\/","title":{"rendered":"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01"},"content":{"rendered":"<div class=\"bpp-post-content\">\n<p style=\"text-align: center;\">\n<p style=\"text-align: center;\"><br  \/><\/p>\n<p style=\"text-align: center;\"><br  \/><\/p>\n<section class=\"\"   style=\"max-width: 100%;box-sizing: border-box;font-size: 16px;font-variant-numeric: normal;font-variant-east-asian: normal;letter-spacing: 0.544px;line-height: 20.48px;white-space: normal;widows: 1;border-width: 0px;border-style: none;border-color: initial;background-color: rgb(255, 255, 255);word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;text-align: center;box-sizing: border-box !important;word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;display: inline-block;width: 2em;box-sizing: border-box !important;word-wrap: break-word !important;\"><img class=\"\"      style=\"display: block;zoom: 0.8;box-sizing: border-box !important;word-wrap: break-word !important;width: 32px !important;visibility: visible !important;\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/9-1554965679.png\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/section>\n<section style=\"margin-top: -6px;max-width: 100%;display: flex;justify-content: center;align-items: center;box-sizing: border-box !important;word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;width: 1em;height: 1px;background: rgb(131, 142, 194);box-sizing: border-box !important;word-wrap: break-word !important;\"><\/section>\n<section class=\"\"  title=\"\" style=\"padding-right: 6px;padding-left: 6px;max-width: 100%;box-sizing: border-box;color: rgb(63, 63, 63);word-wrap: break-word !important;\"><strong>1<\/strong><\/section>\n<section style=\"max-width: 100%;width: 1em;height: 1px;background: rgb(131, 142, 194);box-sizing: border-box !important;word-wrap: break-word !important;\"><\/section>\n<\/section>\n<\/section>\n<\/section>\n<p><span style=\"font-size: 16px;color: rgb(255, 41, 65);\">2016\u5e7411\u670830\u65e5<\/span><span style=\"font-size: 16px;\">\uff0c\u6c5f\u82cf\u6052\u745e\u533b\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7b80\u79f0\u201c\u6052\u745e\u201d\u6216\u201c\u672c\u516c\u53f8\u201d\uff09\u4e0e\u65e5\u672cOncolysBioPharma\u516c\u53f8\uff08\u4ee5\u4e0b\u7b80\u79f0\u201cOncolys\u201d\uff09\u8fbe\u6210\u534f\u8bae\uff0c\u672c\u516c\u53f8\u6709\u507f\u83b7\u5f97Oncolys\u7814\u53d1\u7684\u6eb6\u7624\u817a\u75c5\u6bd2\u4ea7\u54c1<\/span><span style=\"font-size: 16px;color: rgb(255, 41, 65);\">TelomelysinTM\uff08OBP-301\uff09\u5728\u4e2d\u56fd\u5927\u9646\u3001\u9999\u6e2f\u548c\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a<\/span><span style=\"font-size: 16px;\">\uff08\u4ee5\u4e0b\u7b80\u79f0\u201c\u533a\u57df\u5185\u201d\uff09\u7684\u5f00\u53d1\u3001\u751f\u4ea7\u53ca\u5546\u4e1a\u5316\u7684\u72ec\u5bb6\u8bb8\u53ef\u6743\u3002<\/span><\/p>\n<p><br  \/><\/p>\n<p><img class=\"img_respo\"        style=\"width: 100%;height: auto;\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/9-1554965679.jpeg\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/p>\n<p><span style=\"font-size: 16px;\">\u4ea4\u6613\u91d1\u989d\u53ca\u4ed8\u6b3e\u5b89\u6392<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\u3000\u3000<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\u672c\u6b21\u672c\u516c\u53f8\u83b7\u5f97Oncolys\u7814\u53d1\u7684\u6eb6\u7624\u817a\u75c5\u6bd2\u4ea7\u54c1TelomelysinTM(OBP-301)\u5728\u4e2d\u56fd\u5927\u9646\u3001\u9999\u6e2f\u548c\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a\uff08\u4ee5\u4e0b\u7b80\u79f0\u201c\u533a\u57df\u5185\u201d\uff09\u7684\u5f00\u53d1\u3001\u751f\u4ea7\u53ca\u5546\u4e1a\u5316\u7684\u72ec\u5bb6\u8bb8\u53ef\u6743\uff0c\u4ea4\u6613\u91d1\u989d\u4e3a\u4e0d\u8d85\u8fc7\u4e00\u4ebf\u96f6\u4e24\u767e\u4e07\u7f8e\u91d1\u3002\u5305\u62ec\uff1a<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\uff081\uff09\u9996\u4ed8\u6b3e\u4e3a\u4e94\u5341\u4e07\u7f8e\u5143\uff0c\u6839\u636e\u7ea6\u5b9a\u4e8e\u672c\u534f\u8bae\u751f\u6548\u540e\u652f\u4ed8\uff1b<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\uff082\uff09\u5f00\u53d1\u9636\u6bb5\u91cc\u7a0b\u7891\u6b3e\u6700\u9ad8\u4e0d\u8d85\u8fc7\u4e00\u5343\u56db\u767e\u4e94\u5341\u4e07\u7f8e\u5143\uff0c\u9500\u552e\u9636\u6bb5\u91cc\u7a0b\u7891\u6b3e\u6700\u9ad8\u4e0d\u8d85\u8fc7\u516b\u5343\u4e03\u767e\u4e07\u7f8e\u5143\uff0c\u5c06\u6839\u636e\u8fdb\u5ea6\u5206\u6279\u652f\u4ed8\u3002<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\u3000\u3000<\/span><\/p>\n<p><span style=\"font-size: 16px;\">\u6b64\u5916\uff0cTelomelysinTM(OBP-301)\u4ea7\u54c1\u9500\u552e\u63d0\u6210\u7684\u533a\u95f4\u4e3a8%\u81f314%\uff0c\u6052\u745e\u5e94\u5728\u9500\u552e\u63d0\u6210\u671f\u95f4\u6309\u7ea6\u5b9a\u6bd4\u4f8b\u6839\u636e\u4ea7\u54c1\u7684\u5b9e\u9645\u9500\u552e\u989d\u652f\u4ed8\u9500\u552e\u5206\u7ea2\u3002<\/span><\/p>\n<p><span style=\"font-size: 16px;\"><br  \/><\/span><\/p>\n<p><span style=\"font-size: 16px;color: rgb(255, 41, 65);\">\u76ee\u524d\uff0c\u672a\u770b\u5230\u6052\u745e\u533b\u836f\u5728\u8be5\u9879\u76ee\u4e0a\u6709\u5728CDE\u7533\u62a5\u3002<\/span><\/p>\n<p>\u3000<\/p>\n<p><br  \/><\/p>\n<section class=\"\"   style=\"font-variant-numeric: normal;font-variant-east-asian: normal;white-space: normal;max-width: 100%;box-sizing: border-box;font-size: 16px;letter-spacing: 0.544px;line-height: 20.48px;widows: 1;border-width: 0px;border-style: none;border-color: initial;background-color: rgb(255, 255, 255);word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;text-align: center;box-sizing: border-box !important;word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;display: inline-block;width: 2em;box-sizing: border-box !important;word-wrap: break-word !important;\"><img class=\"\"      style=\"display: block;zoom: 0.8;box-sizing: border-box !important;word-wrap: break-word !important;width: 32px !important;visibility: visible !important;\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/8-1554965679.png\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/section>\n<section style=\"margin-top: -6px;max-width: 100%;display: flex;justify-content: center;align-items: center;box-sizing: border-box !important;word-wrap: break-word !important;\">\n<section style=\"max-width: 100%;width: 1em;height: 1px;background: rgb(131, 142, 194);box-sizing: border-box !important;word-wrap: break-word !important;\"><\/section>\n<section class=\"\"  title=\"\" style=\"padding-right: 6px;padding-left: 6px;max-width: 100%;box-sizing: border-box;color: rgb(63, 63, 63);word-wrap: break-word !important;\"><strong>2<\/strong><\/section>\n<section style=\"max-width: 100%;width: 1em;height: 1px;background: rgb(131, 142, 194);box-sizing: border-box !important;word-wrap: break-word !important;\"><\/section>\n<\/section>\n<\/section>\n<\/section>\n<p style=\"white-space: normal;\"><span style=\"font-size: 16px;color: rgb(0, 0, 0);\">2019\u5e744\u67088\u65e5\uff0cOncolys BioPharma Inc.\u548c\u65e5\u672c\u4e2d\u5916\u5236\u836f\uff08\u7f57\u6c0f\u63a7\u80a1\uff09\u5c31Telomelysin (OBP-301)\u8fbe\u6210\u5728\u65e5\u672c\u548c\u4e2d\u56fd\u53f0\u6e7e\u5730\u533a\u7684\u6743\u76ca\u5408\u4f5c\uff0c\u9996\u4ed85.5\u4ebf\u65e5\u5143\u3002<span style=\"color: rgb(0, 0, 0);font-size: 16px;\">Oncolys BioPharma\u65b0\u53d1\u884c\u76848\u4ebf\u65e5\u5143\u80a1\u7968\uff0c\u4e2d\u5916\u5c06\u5168\u90e8\u63a5\u6536\u3002<\/span><\/span><\/p>\n<p style=\"white-space: normal;\"><span style=\"font-size: 16px;color: rgb(0, 0, 0);\"><br  \/><\/span><\/p>\n<p style=\"white-space: normal;\"><span style=\"font-size: 16px;color: rgb(0, 0, 0);\">\u9644\u539f\u6587\uff1a<\/span><\/p>\n<p><span style=\"font-size: 16px;\">TOKYO, April 8, 2019 &#8212; Oncolys BioPharma Inc. (hereafter, \u201cOncolys\u201d) and Chugai Pharmaceutical Co., Ltd.(hereafter, \u201cChugai\u201d) announced today the both companies have entered into an agreement that Oncolys will grant an exclusive license, with sublicensing rights,<\/span><span style=\"font-size: 16px;color: rgb(255, 41, 65);\"> to Chugai concerning the development, manufacturing and marketing in Japan and Taiwan for \u201cTelomelysin (OBP-301)\u201d<\/span><span style=\"font-size: 16px;\"> (hereafter, \u201cTelomelysin\u201d) an oncolytic viral immunotherapy which is currently under development by Oncolys. In addition, licensing agreement that grantsexclusive option rights concerning the worldwide development, manufacturing and marketing of Telomelysin, excluding Japan, Taiwan, China, Hong Kong and Macau to Chugai has also been concluded. <\/span><span style=\"font-size: 16px;color: rgb(255, 41, 65);\">Moreover, both companies agreed that Oncolys will newly issue common stock worth approximately 800 million yen, and Chugai will accept all the stocks.<\/span><span style=\"font-size: 16px;\"> The start of this licensing agreement and the payment accompanying the issuance of new shares by third-party allotment are planned on April 24, 2019.<\/span><\/p>\n<p><br  \/><\/p>\n<p><span style=\"font-size: 16px;color: rgb(255, 41, 65);\">Chugai shall pay 550 million yen as an upfront payment for the exclusive licensing agreement<\/span><span style=\"font-size: 16px;\">, with sublicensing rights, in Japan and Taiwan. If a certain level of efficacy has been confirmed in the clinical study of Telomelysin, and in case Chugai exercised the exclusive option rights described above, the total value of the licensing agreement which Chugai shall pay to Oncolys will be 50 billion yen or more. In addition, after the launch of Telomelysin, Chugai shall pay to Oncolys, sales royalties according to Chugai\u2019s amount of sales of Telomelysin, apart from the total value of the licensing agreement.<\/span><\/p>\n<p><span style=\"font-size: 16px;\"><br  \/><\/span><\/p>\n<p><span style=\"font-size: 16px;\">https:\/\/www.oncolys.com\/en\/<\/span><\/p>\n<p><br  \/><\/p>\n<p style=\"text-align: center;\"><img class=\"rich_pages\"      style=\"\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/10-1554965679.jpg\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/p>\n<p style=\"text-align: center;\"><img class=\"rich_pages\"      style=\"\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/0-1554965679.jpg\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/p>\n<p><br  \/><\/p>\n<p><img class=\"img_respo move\"     src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/1-1554965680.jpeg\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/p>\n<p><br  \/><\/p>\n<p><strong>\u66f4\u591a\u4fe1\u606f\uff0c\u626b\u7801\u5173\u6ce8\u836f\u878d\u6570\u636e\uff01<\/strong><\/p>\n<p style=\"max-width: 100%;min-height: 1em;letter-spacing: 0.544px;white-space: normal;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;word-wrap: break-word !important;\"><img class=\"\"      style=\"zoom: 0.8;box-sizing: border-box !important;word-wrap: break-word !important;visibility: visible !important;width: 449px !important;\" src=\"http:\/\/www.05921.net\/wp-content\/uploads\/2019\/04\/3-1554965680.jpg\" alt=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\" title=\"\u521a\u521a\uff0c\u6052\u745e\u5f15\u8fdb\u6eb6\u7624\u75c5\u6bd2OBP-301\uff1a\u539f\u7814\u4f01\u4e1a\u4e0e\u7f57\u6c0f-\u4e2d\u5916\u5236\u836f\u4ea7\u751f\u5927\u4ea4\u6613\uff01\"  \/><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>1 2016\u5e7411\u670830\u65e5\uff0c\u6c5f\u82cf\u6052\u745e\u533b\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7b80\u79f0\u201c\u6052\u745e\u201d\u6216\u201c\u672c\u516c\u53f8\u201d\uff09\u4e0e\u65e5\u672cOncolysBio [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":81900,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/81899"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=81899"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/81899\/revisions"}],"predecessor-version":[{"id":81908,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/81899\/revisions\/81908"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/81900"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=81899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=81899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=81899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}